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Human granulocyte colony-stimulating factor (G-CSF),' produced by the
bladder carcinoma cell line 5637, has been purified toapparent homogeneity (1)
and molecularly cloned (2). G-CSF purified from both the 5637 cell line and
Escherichia coli support the growth of predominantly neutrophil colonies in a
colony-forming unit of granulocytes/macrophages (CFU-GM) assay, and in the
presence of accessory cells, support the growth of early erythroid progenitors
burst-formingunitoferythrocytes (BFU-E)andpluripotential progenitors (CFU-
GEMM)(granulocytes, erythrocytes, monocytes, andmacrophages) (1-3). G-CSF
is also capable of promoting the differentiation of some myeloid leukemic cell
lines (e.g., HL-60, WEHI-3B-D*) and fresh myeloid leukemic cells (I-3), and
has been reported to enhance the chemotactic peptide binding on peripheral
blood neutrophils (3). In addition, G-CSF can significantly increase the ability of
neutrophils to kill tumor targets in vitro through antibody-dependent cellular
cytotoxicity (ADCC) (4). Initial in vivo results with recombinant human G-CSF
(rhG-CSF) in hamsters indicate a specific action on the neutrophil lineage with
increases ofthree- to sixfold in peripheral blood neutrophils (5). We report here
the in vivo effects of human rhG-CSF in normal and cyclophosphamide (CY)-
treated cynomolgus monkeys (cynomolgus macaque, Macaquefasicularis).
Materials and Methods
Animals.
￿
Primates were obtained from Hazelton Research Animals, Inc., Reston, VA.
Animals used in this study were maintained according to National Institutes of Health
guidelines for the use and care of laboratory animals, and protocols approved by the
Memorial Sloan-Kettering Cancer Center Institutional animal use and care committee.
For administration of rhG-CSF, or bone marrow or blood sampling, the animals were
anesthetized with ketamine hydrochloride (Parke-Davis, Morris Plains, NJ).
G-CSFPreparation.
￿
rhG-CSF expressed in E. coli was purified as described previously
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'Abbreviationsused in thispaper:
￿
ANC, absoluteneutrophilcount;CSF,colony-stimulating factor;
CY, cyclophosphamide; GEMM, granulocyte/erythrocyte/monocyte/macrophage; GM, granulo-
cyte/macrophage; NBT, nitroblue tetrazolium;WBC,whiteblood cell.
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(2, 5) . The homogeneous protein had a concentration of 0.5 mg/ml in 10 mM sodium
acetate buffer, pH 4.1 . Before injections, rhGCSF was diluted to the appropriate concen-
tration in a final volume of 250 jul in saline containing 0.1% heat-inactivated autologous
serum . Endotoxin levels were determined by the Limulus amebocyte lysate assay (Whit-
taker M . A . Bioproducts, Walkersville, MD) and were undetectable . The CSF activity of
the protein (10' U/mg) was determined as described (5) . The rhGCSF was administered
subcutaneously into alternate thighs.
Neutrophil Function Assays .
￿
Peripheral blood neutrophils were separated from hepa-
rinized blood by 3% gelatin sedimentation followed by fractionation over discontinuous
Percoll (Pharmacia Fine Chemicals, Piscataway, NJ) gradients as described (6), and
neutrophils were recovered from the 75% layer . The cell concentration was adjusted to
106 cells/ml .
Chemotaxis was measured using a modification of the method of Boyden (7) . Briefly,
blind well chambers were filled with zymosan (Sigma Chemical Co ., St . Louis, MO) in
HBSS, covered with 5-Am-pore membrane filter (Millipore Corp ., Bedford, MA) and the
top chamber filled with 2 X 105 neutrophils in HBSS containing 2% BSA (Sigma Chemical
Co .) . After incubation (3 h, 37°C), the filters were fixed, stained with hematoxylin, and
cleared in xylene . The number of neutrophils crossing the filter (lower surface) were
counted using a light microscope (x400).
Nitroblue tetrazolium (NBT) reduction was tested according to a method described by
Gifford (8) . Briefly, neutrophils were separated from a single drop of blood by their
propensity to stick to glass, and were exposed to NBT and counterstained with nuclear
fast red . Percentage ofcells containing intracellularblue formazan particles were counted
using a light microscope .
Results and Discussion
Effects of rhG-CSF in Healthy Monkeys.
￿
The effects of rhG-CSF on hemato-
poiesis in vivo were determined initially in two monkeys receiving 10 wg/kg/d
divided in two daily subcutaneous injections for 2-4 wk . The white blood cells
(WBC)countandabsolute neutrophil count(ANC) ofarhG-CSF-treatedmonkey
and a control buffer-treated monkey are shown in Fig. 1A. The WBC count in
the treated monkey increased dramatically 24 h after initiation of treatment, and
by day 6 reached a plateau between 4.2 X 10' and 5.6 X 104 cells/mm', with an
ANC of between 3.1 X 10' and 4.2 X 10' cells/mm' . This WBC level was
maintained throughout the remaining 3 wk of treatment . There was no signifi-
cant change in theWBC orANC ofthe control animal during thesame treatment
period (Fig. I A) . The second animal treated at 10 Ag/kg/d for 14 d showed a
WBC increase from 9 X 105 cells/mm s to a level between 4.86 X 10' and 5.01
X 104 cells/mm' (Fig . I B) . The patternof response to rhG-CSF in both monkeys
receiving 10 icg/kg/d was very similar (Fig . 1, A and B) . To assess the dose
response to rhG-CSF, the second monkey subsequently received a dose of 100
Ag/kg/d for an additional 2 wk (Fig. 1B) . At 100 ug/kg/d, the WBC count
ranged between 8.0 X 10' and 1.20 X 105cells/mm' . In addition,a thirdmonkey
was treated at 1 ug/kg/d for 15 d and exhibited a WBC plateau ranging from
1 .8 X 104 to 2.9 X 10' cells/mm' (Fig. 1 B) . Thesedata indicate adose-dependent
increase inWBC andANC. In both monkeystheWBC countreturned to normal
levels 3 d after rhGCSF treatment (data not shown) .
Analysis of the absolute numbers ofperipheral bloodneutrophils, lymphocytes,
monocytes, erythrocytes, eosinophils, reticulocytes, and platelets was performed
every other day . The increase inWBC was predominantly due to the increase of
absolute numbers of neutrophils (Fig . 1A) . The absolute numbers of eosinophilsWELTE ET AL.
FIGURE 1. Time course ofperipheral bloodWBCandANC ofhealthy cynomolgus monkeys
treated with rhGCSF and a control monkey receiving only buffer. (A) WBC level (10) and
ANC (p) of a healthy monkey treated with 10 hg/kg/d rhG-CSFsubcutaneously in two daily
doses.The WBC level (A)and ANC(A) ofthecontrol monkey is also shownin A. (B) Effects
o£different concentrationsof rhGCSF: (A), 1 ug/kg/d;(1$), 10 ug/kg/d; and("), 100,ug/kg/d.
Note that the monkey receiving 10 lAg/kg/d was subsequently treated with 100 ug/kg/d, and
thereforeday 0of 100wg/kg/dcorresponds to day 16 of 10 wg/kg/d.
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andmonocytes did notchangesignificantly. There wasadose-dependentincrease
in the absolute number of lymphocytes (1.5-2.5-fold) in monkeys receiving 10
.ug/kg/d or 100 ,ug/kg/d. The majority (~80%) ofperipheral blood lymphocytes
were found to be T cells, as assessed by reactivity with the anti-human T cell
antibody TI 1. No significant changes in erythrocyte, reticulocyte, or platelet
counts or hemoglobin concentrations were noted.
The monkey receiving 10 ug/kg/d for 28 d and the control monkey were
sacrificed on day 29. Before sacrifice, peripheral blood smears were made and
stained (Giemsa) fordifferential cellcounts (Fig. 2A). Neutrophils predominated
in the blood smear from the rhG-CSF-treated monkey. Immediately after sacri-
fice, sternal bone marrow specimens were taken for histologic examination,
serially dehydrated, and embedded in plastic for thin sectioning. Sections of the
bone marrow from the treated monkey demonstrated hypercellularity and a
predominance ofneutrophil precursors (Fig. 2B). The numbers of myeloblasts,
promyelocytes, myelocytes, and bands were increased 5-10-fold over those in
the specimen from the control monkey.
Extramedullary Hematopoiesis.
￿
The spleen of the
increased in size or weight, but showed prominent white follicles on the subcap-
sular and cut surfaces. Histologically, the internodular areas were filled with
mature granulocytes and foci of extramedullary myelopoiesis, demonstrating
myeloblasts and myelocytes. Generally lymph nodes were increased twofold in
size due to lymphoid hypercellularity, and occasional foci of extramedullary944 RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR
FIGURE 2.
￿
Effect of rhG-CSFon normal andCY-treated monkeys . Peripheral blood smears,
bone marrow smears andbone marrow biopsy specimenswere prepared and stained according
to the May-Grunwald-Giemsa technique . (A) Peripheral blood smears ; (1) from a control
monkey, demonstrating normal numbers and distribution of cells; and (2) from a monkey
treated with 10 jug/kg/d o¬rhGCSF for 28 d, showinga significant neutrophilia. x 400. (B)
Marrow biopsies showingnormal proportions of erythroid and other myeloid elements from
an untreated monkey (l) and predominance of granulocytes and their precursors in an rhG
CSF treatedmonkey (2) . x500. (C)Monkey bone marrow aspiratestaken2wk aftertreatment
with CY . Hypocellularity is present in the specimen from the monkey that received only CY
(1), whilethebone marrow smearfrom a similarly treated monkey, also givenrhGCSFstarting
on the third day after the second dose of CY, shows normal cellularity, with all elements
present and apredominance ofgranulocytes and their precursors (2). x 400 .
myelopoiesis (bands, myelocytes, promyelocytes, and myeloblasts) were observed .
The thymus was moderately enlarged, and rare foci of myelopoiesis were noted .
No otherorgans (e.g ., liver, kidney, etc.) demonstrated evidence ofhematopoietic
activity . No toxicity was seen by clinical or laboratory examination.WELTE ET AL .
￿
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TABLE I
Peripheral Blood Neutrophil Functions of rhG-CSF-treated Monkeys
Peripheral blood neutrophil functions of control and rhGCSF (>>-10
kg/kg/d) treated monkeys . Peripheral blood neutrophils were isolated
from monkeys on the 21st day of treatment, and separated as described (6) .
* Chemotaxis is measured as the number of neutrophils (mean of five
random fields) crossing a 5-km filter using zymosan as the chemoattract-
ant. The results are shown as mean t SD, with or without zymosan as
the chemoattractant.
* The percentage of neutrophils (>_100 cells examined) containing intra-
cellular blue formazan particles.
Neutrophil Functions.
￿
In view of the dramatic peripheral blood neutrophilia
in animals receiving rhG-CSF, we measured the neutrophil activities in vitro on
the 21st day of treatment . As shown in Table I, the neutrophils of treated
monkeys functioned normally in a standard test for chemotaxis . Neutrophils
were then tested for their ability to reduce NBT as measured by the percentage
of cells containing intracellular blue formazan particles . ^-73% ofthe neutrophils
recovered from treated animals contained intracellular blue formazan particles,
whereas only 35% of the cells from the control animal contained such particles
(Table I) . These results indicate that the expanded pool of neutrophils in treated
animals are functionally normal and may have an enhanced ability kill to
phagocytized bacteria .
Effects of rhG-CSF in CY-treated Monkeys .
￿
To test the effect of rhG-CSF in
chemotherapy-induced cytopenia, we treated three monkeys with CY (60
mg/kg/d, two doses) . This dosage leads to bone marrow aplasia and peripheral
blood pancytopenia by day 4-7 after treatment . Two of the three monkeys also
received rhG-CSF (10 wg/kg/d), while the third received only CY . As shown in
Fig . 3, one monkey received rhG-CSF for 14 d, starting 72 h after the last dose
ofCY . By the day after the first day ofrhG-CSF, theWBC count in this monkey
rose from 2 .3 X 103 to 7 X 103 , and then fell to 4 X 10 2' and 3.7 X 10' in the
subsequent 2 d . This brief rise in theWBC was most likely due to demargination
of neutrophils . A second monkey was treated with rhG-CSF for 6 d before CY,
during the CY administration, and for an additional 21 d . This monkey acquired
a peripheral WBC level of 5.23 X 104 cells/mm' before CY treatment . The first
dose of CY did not lead to an expected decrease of the peripheral WBC, but
rather was followed by a continued increase to 7.1 X 10' cells/mm . The WBC
counts declined in all three monkeys to a level under 2.5X 103 cells/mm3 by day
4 after CY, and in the rhG-CSF-pretreated monkey, to a brief and transient
nadir of 200 WBC by day 6 . In both rhG-CSF-treated monkeys, the peripheral
WBC increased dramatically by day 6-7 after CY, reaching levelsof-5.0 X 104
WBC/mm3 by the IOth day after CY . TheseWBC levels are similar to those seen
In vivo
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FIGURE 3. Time course of peripheral blood WBC of three monkeys treated with CY
(Cytoxan; Bristol Meyers, Syracuse, NY; 60 mgAg/d, two doses, treatment designated by
arrows on days 0 and 1): (N), control monkey; (,h), monkey treated with rhG-CSF starting 72
h after the last dose of CY until day 17 after CY; and ("), monkey pretreated with rhG-CSF
starting 6 dbefore CY and continued treatment to day 20 afterCY. The rhGCSF treatment
period is designated for each animal: (t-), post-CY-treated, and(D-), pre-CY-treated.
in normal monkeys receiving only rhG-CSF at the same dose. The ANC ranged
between 90 and 100% from day 7 to day 20 after CY, while lymphocytes
remained <10% and monocytes <2% during the same time period. After
cessation of rhG-CSF administration, the WBC count never dropped below
normal levels. The percentage of neutrophils also returned to normal values
(30-40%). In contrast, the control monkey remained pancytopenic, with WBC
levels <4 X 10s cells/mms, up to 4 wk after CY treatment (Fig. 3). As shown in
Fig. 2C, the bone marrow aspirate (day 14 after CY) of the rhG-CSF-treated
monkey showed evidence of recovery of all cell lineage precursors, whereas the
control monkey (CY alone) demonstrated persistent hypocellularity. The timeWELTE ET AL.
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course of post-CY platelet recovery was similar in all three monkeys (rhG-CSF-
treated or control), requiring ^-2 wk to return to normal levels.
The early recovery after CY suggests that the availability of this growth factor
is one of the critical limiting steps in the proliferation and differentiation ofbone
marrow progenitor cells after CY treatment. The dramatic recovery of neutro-
phils in the rhG-CSF-treated monkeysafter CY is also indicative of the functional
integrity of progenitor cells capable of responding to rhG-CSF. These data
suggest, however, that pretreatment with rhGCSF does not prevent CY-induced
cytopenia when given in the regimen described herein.
Summary
We examined the in vivo effects of recombinant human granulocyte colony-
stimulating factor (rhG-CSF) in primates (cynomolgus monkeys) treated with
subcutaneous doses of rhG-CSF for 14-28 d. A dose-dependent increase in the
peripheral white blood cells (WBC) was seen, reaching a plateau after 1 wk of
rhG-CSFtreatment. The elevation ofWBC was due to an increase in theabsolute
neutrophil count. These results demonstrate that rhG-CSF is a potent granulo-
poietic growth and differentiation factor in vivo. In cyclophosphamide (CY)-
inducedmyelosuppression, rhG-CSF was able to shorten the time period of WBC
recovery in two treated monkeys to 1 wk, as compared to more than 4 wk for
the control monkey. Its ability to significantly shorten the period of chemother-
apy-induced bone marrow hypoplasia may allow clinicians to increase the fre-
quency or dosage of chemotherapeutic agents. In addition, the increase in
absolute numbers of functionally active neutrophils may have a profound effect
in the rate and severity of neutropenia-related sepsis. Furthermore, theactivities
reported here indicate a potential role for rhG-CSF in the treatment of patients
with myelodysplastic syndrome, congenital agranulocytosis, radiation-induced
myelosuppression, and bone marrow transplantation.
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